Skip to Content

Clindamycin / tretinoin topical Disease Interactions

There are 3 disease interactions with clindamycin / tretinoin topical:

Major

Retinoid/retinoid-like topical (Includes clindamycin/tretinoin topical) ↔ eczema

Severe Potential Hazard, High plausibility. Applies to: Eczema

Topical retinoids may cause severe irritation on eczematous skin. Therapy with topical retinoids should be avoided on abraded or eczematous skin.

References

  1. "Product Information. Differin (adapalene topical)." Galderma Laboratories Inc, Fort Worth, TX.
  2. "Product Information. Tazorac (tazarotene topical)." Allergan Inc, Irvine, CA.
  3. "Product Information. Retin-A (tretinoin)." Ortho Pharmaceutical Corporation, Raritan, NJ.
Major

Topical clindamycin (Includes clindamycin/tretinoin topical) ↔ colitis

Severe Potential Hazard, Moderate plausibility. Applies to: Colitis/Enteritis (Noninfectious)

Clindamycin may be systemically absorbed when applied to the skin or mucosal membranes. Pseudomembranous colitis has been reported with systemically as well as topically administered clindamycin and may range in severity from mild to life-threatening, with an onset of up to several weeks following cessation of therapy. The colitis is usually characterized by severe, persistent diarrhea and severe abdominal cramps, and may be associated with the passage of blood and mucus. Therapy with topical clindamycin should be administered cautiously in patients with a history of gastrointestinal diseases, particularly colitis. There is some evidence that pseudomembranous colitis, if it occurs, may run a more severe course in these patients and that it may be associated with flares in their underlying disease activity. Certain products may be contraindicated by the manufacturer, and prescribers are advised to consult the package labeling. Clindamycin should be discontinued if significant diarrhea occurs during therapy. Stool cultures for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically. A large bowel endoscopy may be considered to establish a definitive diagnosis in cases of severe diarrhea.

References

  1. Borglund E, Hagermark O, Nord CE "Impact of topical clindamycin and systemic tetracycline on the skin and colon microflora in patients with acne vulgaris." Scand J Infect Dis Suppl 43 (1984): 76-81
  2. Vikenes K, LundTonnesen S, Schreiner A "Clostridium difficile-associated diarrhea after short term vaginal administration of clindamycin." Am J Gastroenterol 94 (1999): 1969-70
  3. Voron DA "Systemic absorption of topical clindamycin." Arch Dermatol 114 (1978): 798
  4. Davies J, Beck E "Recurrent colitis following antibiotic-associated pseudomembranous colitis." Postgrad Med J 57 (1981): 599-601
  5. Milstone EB, McDonald AJ, Scholhamer CF Jr "Pseudomembranous colitis after topical application of clindamycin." Arch Dermatol 117 (1981): 154-5
  6. Leigh DA, Simmons K, Williams S "Gastrointestinal side effects following clindamycin and lincomycin treatment: a follow up study." J Antimicrob Chemother 6 (1980): 639-45
  7. Meadowcroft AM, Diaz PR, Latham GS "Clostridium difficile toxin-induced colitis after use of clindmycin phosphate vaginal cream." Ann Pharmacother 32 (1998): 309-11
  8. Trexler MF, Fraser TG, Jones MP "Fulminant pseudomembranous colitis caused by clindamycin phosphate vaginal cream." Am J Gastroenterol 92 (1997): 2112-3
  9. Van Ness MM, Cattau EL Jr "Fulminant colitis complicating antibiotic-associated pseudomembranous colitis: case report and review of the clinical manifestations and treatment." Am J Gastroenterol 82 (1987): 374-7
  10. Gallerani M, Ricci L, Calo G, Manfredini R "Abdominal pain and diarrhoea caused by topical clindamycin phosphate." Clin Drug Invest 14 (1997): 243-5
  11. Parry MF, Rha CK "Pseudomembranous colitis caused by topical clindamycin phosphate." Arch Dermatol 122 (1986): 583-4
  12. Siegle RJ, Fekety R, Sarbone PD, Finch RN, Deery HG, Voorhees JJ "Effects of topical clindamycin on intestinal microflora in patients with acne." J Am Acad Dermatol 15 (1986): 180-5
  13. Cone JB, Wetzel W "Toxic megacolon secondary to pseudomembranous colitis." Dis Colon Rectum 25 (1982): 478-82
  14. Fisher AA "Adverse reactions to topical clindamycin, erythromycin and tetracycline." Cutis 32 (1983): 415,419,424,428
View all 14 references
Moderate

Retinoid/retinoid-like topical (Includes clindamycin/tretinoin topical) ↔ sunburn

Moderate Potential Hazard, High plausibility. Applies to: Sunburn

Retinoid-like products can cause extreme irritation when applied to sunburned skin. Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.

References

  1. "Product Information. Differin (adapalene topical)." Galderma Laboratories Inc, Fort Worth, TX.
  2. "Product Information. Tazorac (tazarotene topical)." Allergan Inc, Irvine, CA.
  3. "Product Information. Retin-A (tretinoin)." Ortho Pharmaceutical Corporation, Raritan, NJ.
  4. Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989): 346
View all 4 references

Clindamycin / tretinoin topical drug interactions

There are 22 drug interactions with clindamycin / tretinoin topical

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide